Phase 3 Endometrial Cancer Trial, Recruiting NCT03534713 Sponsor: University Hospital, Toulouse Condition: Endometrial Cancer
Back to Endometrial Cancer

Phase 3 Endometrial Cancer Trial, Recruiting

NCT03534713
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are a woman diagnosed with cervical cancer that has been confirmed by a tissue biopsy and has spread to lymph nodes near the large blood vessel in the abdomen (called para-aortic lymph nodes), confirmed by a special scan or surgical biopsy
  • Your cancer is at a stage between IB1 and IVA (meaning it has not spread to distant organs beyond the para-aortic lymph nodes)
  • Your cancer is one of these types: squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma
  • You are well enough to carry out light daily activities (your general health is rated as reasonably good by your doctor)
  • Your kidneys are working well enough (confirmed by a blood test)
  • Your liver is working well enough (confirmed by a blood test)
  • Your blood counts (platelets and white blood cells) are at acceptable levels
  • You are willing and able to give written consent to take part

Who may not be able to join:

  • Your cervical cancer has already spread to distant parts of the body beyond the abdomen (stage IVB)
  • Your cervical cancer is a type other than squamous cell, adenocarcinoma, or adenosquamous carcinoma
  • You have already received chemotherapy for your cervical cancer
  • You are currently pregnant or breastfeeding
  • You have had another cancer (other than certain common skin cancers) within the last 5 years
  • Your kidneys, liver, or blood counts are not working at the required levels
  • You have a significant heart condition affecting your daily activity (confirm with trial site)
  • You already have moderate or severe nerve damage causing symptoms such as numbness or tingling in your hands or feet (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Stéphanie MOTTON, MD, University Hospital, Toulouse

Phone: +335 61 32 37 08

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
17 July 2020
Est. completion
1 September 2026

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Overall survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov